Hypersensitivity Pneumonitis Market size was valued at USD 1.06 Billion in 2023 and is likely to reach USD 2.32 Billion by 2036, registering around 6.2% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of hypersensitivity pneumonitis is estimated at USD 1.12 Billion. The reason behind the growth is impelled by the increasing prevalence of respiratory diseases across the globe. The third biggest cause of mortality is chronic respiratory conditions caused by risk factors including allergens, occupational dangers, and tobacco use. This has increased awareness regarding such conditions among people, leading to better treatment options for hypersensitivity pneumonitis as well. Each year, asthma accounts for more than 160 000 fatalities worldwide.
The development of non-invasive diagnostic procedures are believed to fuel the hypersensitivity pneumonitis market. Imaging and spirometry are non-invasive techniques used in diagnosis and the measurement of the lung's capacity to inhale and exhale air. For instance, HRCT is a noninvasive, precise diagnostic technology used for the proper diagnosis of chronic hypersensitivity pneumonitis.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
6.2% |
|
Base Year Market Size (2023) |
USD 1.06 Billion |
|
Forecast Year Market Size (2036) |
USD 2.32 Billion |
|
Regional Scope |
|
Treatment (Immunosuppressive, Corticosteroids)
The corticosteroids segment is estimated to account for 60% share of the global hypersensitivity pneumonitis market in the coming years owing to the benefits provided by this treatment. Corticosteroids are considered in patients with severe lung function impairment as both low-dose oral corticosteroids provide adequate initial treatment of acute hypersensitivity pneumonitis. Corticosteroids improve survival and slow fibrotic progression in a matched cohort and the therapy may accelerate the initial recovery in persons with severe disease. For instance, corticosteroids such as prednisone usually 60 mg orally once a day for 1 to 2 weeks, are prescribed for severe symptoms or significant lung dysfunction.
End-User (Hospital, Online Pharmacy, Drug Stores, Retail Pharmacy)
Hypersensitivity pneumonitis market from the hospital segment is set to garner a notable share shortly on account of growing advancements in diagnostic techniques. Hospitals are equipped with advanced tools for diagnosis of various diseases including hypersensitivity pneumonitis. This may lead to more patients visiting hospitals for managing acute to severe cases of hypersensitivity pneumonitis.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
Treatment |
|
|
End-User |
|
North American Market Forecast
Hypersensitivity pneumonitis market in North America is predicted to account for the largest share of 37% by 2036 impelled by the increasing spending in healthcare. This would allocate more resources to the healthcare which may improve the diagnostic capabilities and provide access to treatments for people with hypersensitivity pneumonitis.
According to estimates, Healthcare costs in the US are currently rising by over 1% faster than the GDP every year and by 2028 spending on healthcare in the United States will total more than USD 6 trillion.
European Market Statistics
The Europe hypersensitivity pneumonitis market is estimated to be the second largest, during the forecast timeframe led by growing healthcare awareness. Various campaigns and awareness programs are being conducted in the region which has led to an increase in public knowledge about the hypersensitivity pneumonitis disease. As a result, more and more people are being diagnosed with the disease.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?